Umbilical-cord blood transplantation for the treatment of cancer

Juliet N. Barker, John E. Wagner

Research output: Contribution to journalReview articlepeer-review

115 Scopus citations


Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited by the lack of suitable bone-marrow donors, the risk of graft-versus-host disease (GVHD) and slow immune reconstitution. Umbilical-cord blood is an alternative source of haematopoietic stem cells that has recently been tested in both child and adult cancer patients. These studies have identified several advantages to umbilical-cord cell transplantation, including a lower incidence of GVHD. Umbilical-cord blood is therefore a promising alternative to bone-marrow-derived stem cells.

Original languageEnglish (US)
Pages (from-to)526-532
Number of pages7
JournalNature Reviews Cancer
Issue number7
StatePublished - Jul 2003

Bibliographical note

Funding Information:
Supported by grants from the National Institutes of Health and the Children’s Cancer Research Fund.


Dive into the research topics of 'Umbilical-cord blood transplantation for the treatment of cancer'. Together they form a unique fingerprint.

Cite this